Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Leukemia

Free Subscription 28.01.2019 6 Ann Hematol 3 Blood 1 BMC Cancer 4 Bone Marrow Transplant 2 Br J Cancer 1 Cancer 1 Cancer Chemother Pharmacol 1 Cancer Res 1 Cell 1 Clin Infect Dis 1 Eur J Immunol 1 Exp Hematol 1 Int J Hematol 2 J Biol Chem 3 J Clin Oncol 1 J Immunol 2 J Pediatr Hematol Oncol 5 Leuk Lymphoma 6 Leuk Res 6 Leukemia 1 Oncogene 1 Oncol Rep 3 PLoS One

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Ann Hematol

1. WANNER D, Bohn JP, Rudzki J, Stockhammer G, et al
   Autoimmune myelitis in a CLL patient undergoing treatment with ibrutinib.
   Ann Hematol. 2019;98:205-207.
   PubMed     Text format    
   
   
2. CHEUNG E, Perissinotti AJ, Bixby DL, Burke PW, et al
   The leukemia strikes back: a review of pathogenesis and treatment of secondary AML.
   Ann Hematol. 2019 Jan 21. pii: 10.1007/s00277-019-03606.
   PubMed     Text format     Abstract available
   
   
3. OKUYAMA S, Nito T, Yanagawa N, Tajima K, et al
   Giant cellulitis-like Sweet syndrome as an initial clinical presentation of acute myeloblastic leukemia with t(6;9)(p23;q34): DEK-CAN and internal duplications of FMS-like tyrosine kinase 3.
   Ann Hematol. 2019 Jan 18. pii: 10.1007/s00277-019-03613.
   PubMed     Text format    
   
   
4. KAWASHIMA N, Akashi A, Nagata Y, Kihara R, et al
   Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study.
   Ann Hematol. 2019;98:83-91.
   PubMed     Text format     Abstract available
   
   
5. XIAOSU Z, Leqing C, Yazhen Q, Yu W, et al
   Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease determined by CBFbeta/MYH11 gene expression.
   Ann Hematol. 2019;98:73-81.
   PubMed     Text format     Abstract available
   
   
6. GAO XN, Lin J, Wang SH, Huang WR, et al
   Donor lymphocyte infusion for prevention of relapse after unmanipulated haploidentical PBSCT for very high-risk hematologic malignancies.
   Ann Hematol. 2019;98:185-193.
   PubMed     Text format     Abstract available
   
   

   
   Blood

7. NAKADA D
   ENLightening YEATS in antagonizing polycomb repression.
   Blood. 2018;131:591.
   PubMed     Text format    
   
   
8. NIEMEYER CM, Flotho C
   Juvenile myelomonocytic leukemia: who's the driver at the wheel?
   Blood. 2019 Jan 22. pii: blood-2018-11-844688. doi: 10.1182/blood-2018-11-844688
   PubMed     Text format     Abstract available
   
   
9. STOCK W, Luger SM, Advani AS, Yin J, et al
   A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.
   Blood. 2019 Jan 18. pii: blood-2018-10-881961. doi: 10.1182/blood-2018-10-881961
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

10. CHI VLD, Garaud S, De Silva P, Thibaud V, et al
    Age-related changes in the BACH2 and PRDM1 genes in lymphocytes from healthy donors and chronic lymphocytic leukemia patients.
    BMC Cancer. 2019;19:81.
    PubMed     Text format     Abstract available
    
    

    
    Bone Marrow Transplant

11. HAMILTON BK, Rybicki L, Hirsch C, Przychodzen B, et al
    Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes.
    Bone Marrow Transplant. 2019 Jan 17. pii: 10.1038/s41409-019-0444.
    PubMed     Text format     Abstract available
    
    
12. WIKTOR-JEDRZEJCZAK W, Drozd-Sokolowska J, Eikema DJ, Hoek J, et al
    EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL).
    Bone Marrow Transplant. 2019 Jan 21. pii: 10.1038/s41409-019-0448.
    PubMed     Text format     Abstract available
    
    
13. FUJI S, Yamaguchi T, Inoue Y, Utsunomiya A, et al
    VCAP-AMP-VECP as a preferable induction chemotherapy in transplant-eligible patients with aggressive adult T-cell leukemia-lymphoma: a propensity score analysis.
    Bone Marrow Transplant. 2019 Jan 21. pii: 10.1038/s41409-019-0446.
    PubMed     Text format     Abstract available
    
    
14. DAHLBERG A, Leisenring W, Bleakley M, Meshinchi S, et al
    Prognosis of relapse after hematopoietic cell transplant (HCT) for treatment of leukemia or myelodysplastic syndrome (MDS) in children.
    Bone Marrow Transplant. 2019 Jan 22. pii: 10.1038/s41409-019-0438.
    PubMed     Text format     Abstract available
    
    

    
    Br J Cancer

15. DOSS M
    Comment on '30 years follow-up and increased risks of breast cancer and leukaemia after long-term low-dose-rate radiation exposure'.
    Br J Cancer. 2018 Feb 13. pii: bjc2017481. doi: 10.1038/bjc.2017.
    PubMed     Text format    
    
    
16. HSIEH WH, Lin IF, Ho JC, Chang PW, et al
    Reply to 'Comment on '30 years follow-up and increased risks of breast cancer and leukaemia after long-term low-dose-rate radiation exposure''.
    Br J Cancer. 2018 Feb 13. pii: bjc2017490. doi: 10.1038/bjc.2017.
    PubMed     Text format    
    
    

    
    Cancer

17. KANTARJIAN HM, Jabbour EJ, Garcia-Manero G, Kadia TM, et al
    Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia.
    Cancer. 2019 Jan 22. doi: 10.1002/cncr.31923.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Chemother Pharmacol

18. SCHOCH LK, Asiama A, Zahurak M, Shanbhag S, et al
    Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients.
    Cancer Chemother Pharmacol. 2018;81:347-354.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Res

19. CARTER BZ, Mak PY, Wang X, Tao W, et al
    An ARC-regulated IL1beta/Cox-2/PGE2/beta-catenin/ARC circuit controls leukemia-microenvironment interactions and confers drug resistance in AML.
    Cancer Res. 2019 Jan 23. pii: 0008-5472.CAN-18-0921.
    PubMed     Text format     Abstract available
    
    

    
    Cell

20. HOSHII T, Cifani P, Feng Z, Huang CH, et al
    A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response.
    Cell. 2018;172:1007-1021.
    PubMed     Text format     Abstract available
    
    

    
    Clin Infect Dis

21. MCGUFFIN SA, Bharadwaj R, Gonzalez-Cuyar LF, Schiffer JT, et al
    In the Eye of the Beholder: A Conjunctival Lesion in a Woman With Acute Myelogenous Leukemia.
    Clin Infect Dis. 2019;68:525-529.
    PubMed     Text format    
    
    

    
    Eur J Immunol

22. SONG Y, Hu B, Liu Y, Jin Z, et al
    IL-12/IL-18-preactivated donor NK cells enhance GVL effects and mitigate GvHD after allogeneic hematopoietic stem cell transplantation.
    Eur J Immunol. 2018;48:670-682.
    PubMed     Text format     Abstract available
    
    

    
    Exp Hematol

23. TURHAN AG, Foudi A, Hwang JW, Desterke C, et al
    MODELING MALIGNANCIES USING INDUCED PLURIPOTENT STEM CELLS: FROM CHRONIC MYELOID LEUKEMIA (CML) TO HEREDITARY CANCERS.
    Exp Hematol. 2019 Jan 16. pii: S0301-472X(19)30008.
    PubMed     Text format     Abstract available
    
    

    
    Int J Hematol

24. TANAKA Y, Takahashi Y, Tanaka R, Miyagi T, et al
    Association of high levels of plasma OX40 with acute adult T-cell leukemia.
    Int J Hematol. 2019 Jan 16. pii: 10.1007/s12185-018-02580.
    PubMed     Text format     Abstract available
    
    

    
    J Biol Chem

25. BRUINSMA S, James DJ, Quintana Serrano M, Esquibel J, et al
    Small molecules that inhibit the late stage of Munc13-4-dependent secretory granule exocytosis in mast cells.
    J Biol Chem. 2018;293:8217-8229.
    PubMed     Text format     Abstract available
    
    
26. ZHANG H, Coblentz C, Watanabe-Smith K, Means S, et al
    Gain-of-function mutations in granulocyte colony-stimulating factor receptor (CSF3R) reveal distinct mechanisms of CSF3R activation.
    J Biol Chem. 2018;293:7387-7396.
    PubMed     Text format     Abstract available
    
    

    
    J Clin Oncol

27. CRADDOCK C, Slade D, De Santo C, Wheat R, et al
    Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia.
    J Clin Oncol. 2019 Jan 17:JCO1800889. doi: 10.1200/JCO.18.00889.
    PubMed     Text format     Abstract available
    
    
28. COOK LB, Fuji S, Hermine O, Bazarbachi A, et al
    Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report.
    J Clin Oncol. 2019 Jan 18:JCO1800501. doi: 10.1200/JCO.18.00501.
    PubMed     Text format     Abstract available
    
    
29. PUI CH, Rebora P, Schrappe M, Attarbaschi A, et al
    Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Retrospective Multinational Study.
    J Clin Oncol. 2019 Jan 18:JCO1800822. doi: 10.1200/JCO.18.00822.
    PubMed     Text format     Abstract available
    
    

    
    J Immunol

30. BALLESTEROS-ARIAS L, Silva JG, Paiva RA, Carbonetto B, et al
    T Cell Acute Lymphoblastic Leukemia as a Consequence of Thymus Autonomy.
    J Immunol. 2019 Jan 16. pii: jimmunol.1801373. doi: 10.4049/jimmunol.1801373.
    PubMed     Text format     Abstract available
    
    

    
    J Pediatr Hematol Oncol

31. HOLMES EA, Friedman DL, Connelly JA, Dulek DE, et al
    Impact of IgG Monitoring and IVIG Supplementation on the Frequency of Febrile Illnesses in Pediatric Acute Lymphoblastic Leukemia Patients Undergoing Maintenance Chemotherapy.
    J Pediatr Hematol Oncol. 2019 Jan 16. doi: 10.1097/MPH.0000000000001415.
    PubMed     Text format     Abstract available
    
    
32. FU Y, Wang H, Zhai X, Qian X, et al
    Improved Outcome of Newly Diagnosed Childhood Mature B-Cell Lymphoma/Leukemia With High Tumor Burden Treated With BFM95-based Protocol Combining Rituximab: A Report From Shanghai, China.
    J Pediatr Hematol Oncol. 2019 Jan 16. doi: 10.1097/MPH.0000000000001419.
    PubMed     Text format     Abstract available
    
    

    
    Leuk Lymphoma

33. BEWERSDORF JP, Stahl M, Zeidan AM
    Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?
    Leuk Lymphoma. 2019 Jan 17:1-16. doi: 10.1080/10428194.2018.1546854.
    PubMed     Text format     Abstract available
    
    
34. ECTOR GICG, Govers TM, Westerweel PE, Grutters JPC, et al
    The potential health gain and cost savings of improving adherence in chronic myeloid leukemia.
    Leuk Lymphoma. 2019 Jan 22:1-8. doi: 10.1080/10428194.2018.1535113.
    PubMed     Text format     Abstract available
    
    
35. SHIPOUNOVA IN, Petinati NA, Bigildeev AE, Sorokina TV, et al
    Alterations in multipotent mesenchymal stromal cells from the bone marrow of acute myeloid leukemia patients at diagnosis and during treatment.
    Leuk Lymphoma. 2019 Jan 22:1-8. doi: 10.1080/10428194.2018.1554861.
    PubMed     Text format     Abstract available
    
    
36. KHOT A
    Where do we currently stand with T-cell prolymphocytic leukemia?
    Leuk Lymphoma. 2019 Jan 22:1-3. doi: 10.1080/10428194.2018.1551543.
    PubMed     Text format    
    
    
37. RITCHIE EK, Latremouille-Viau D, Guerin A, Pivneva I, et al
    Tyrosine kinase inhibitor therapy treatment and discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States: a clinical practice perspective.
    Leuk Lymphoma. 2019 Jan 22:1-9. doi: 10.1080/10428194.2018.1538510.
    PubMed     Text format     Abstract available
    
    

    
    Leuk Res

38. NAJIMA Y, Yoshida C, Iriyama N, Fujisawa S, et al
    Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first study.
    Leuk Res. 2018;66:66-72.
    PubMed     Text format     Abstract available
    
    
39. SINGH M, Bhatia P, Trehan A, Varma N, et al
    High frequency of intermediate and poor risk copy number abnormalities in pediatric cohort of B-ALL correlate with high MRD post induction.
    Leuk Res. 2018;66:79-84.
    PubMed     Text format     Abstract available
    
    
40. LI L, Cui Y, Shen J, Dobson H, et al
    Evidence for activated Lck protein tyrosine kinase as the driver of proliferation in acute myeloid leukemia cell, CTV-1.
    Leuk Res. 2019;78:12-20.
    PubMed     Text format     Abstract available
    
    
41. BUDNIK J, Milano MT
    A registry-based analysis of survival outcomes in mast cell leukemia.
    Leuk Res. 2019;78:24-28.
    PubMed     Text format     Abstract available
    
    
42. MEDEIROS BC, Othus M, Tallman MS, Sun Z, et al
    The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900).
    Leuk Res. 2019;78:29-33.
    PubMed     Text format     Abstract available
    
    
43. CIANGOLA G, Gurnari C, Paterno G, Mirabile M, et al
    STAT5b-RARa-positive acute myeloid leukemia: Diagnostic and therapeutic challenges of a rare AML subtype.
    Leuk Res. 2019;78:21-23.
    PubMed     Text format    
    
    

    
    Leukemia

44. ALFONSO V, Iaccarino L, Ottone T, Cicconi L, et al
    Early and sensitive detection of PML-A216V mutation by droplet digital PCR in ATO-resistant acute promyelocytic leukemia.
    Leukemia. 2019 Jan 16. pii: 10.1038/s41375-018-0298.
    PubMed     Text format    
    
    
45. HOFFMANN H, Thiede C, Glauche I, Kramer M, et al
    The prognostic potential of monitoring disease dynamics in NPM1-positive acute myeloid leukemia.
    Leukemia. 2019 Jan 23. pii: 10.1038/s41375-018-0371.
    PubMed     Text format    
    
    
46. NABINGER SC, Chen S, Gao R, Yao C, et al
    Mutant p53 enhances leukemia-initiating cell self-renewal to promote leukemia development.
    Leukemia. 2019 Jan 23. pii: 10.1038/s41375-019-0377.
    PubMed     Text format    
    
    
47. BACCARANI M, Castagnetti F, Gugliotta G, Rosti G, et al
    The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview.
    Leukemia. 2019 Jan 23. pii: 10.1038/s41375-018-0341.
    PubMed     Text format     Abstract available
    
    
48. FIORCARI S, Benatti S, Zucchetto A, Zucchini P, et al
    Overexpression of CD49d in trisomy 12 chronic lymphocytic leukemia patients is mediated by IRF4 through induction of IKAROS.
    Leukemia. 2019 Jan 18. pii: 10.1038/s41375-018-0296.
    PubMed     Text format    
    
    
49. ESTEY E, Othus M, Gale RP
    New study-designs to address the clinical complexity of acute myeloid leukemia.
    Leukemia. 2019 Jan 22. pii: 10.1038/s41375-018-0363.
    PubMed     Text format    
    
    

    
    Oncogene

50. SOMERS K, Wen VW, Middlemiss SMC, Osborne B, et al
    A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction.
    Oncogene. 2019 Jan 22. pii: 10.1038/s41388-018-0666.
    PubMed     Text format     Abstract available
    
    

    
    Oncol Rep

51. PILLOZZI S, Bernini A, Spiga O, Lelli B, et al
    Peptides and small molecules blocking the CXCR4/CXCL12 axis overcome bone marrowinduced chemoresistance in acute leukemias.
    Oncol Rep. 2019;41:312-324.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

52. BALLO O, Tarazzit I, Stratmann J, Reinheimer C, et al
    Colonization with multidrug resistant organisms determines the clinical course of patients with acute myeloid leukemia undergoing intensive induction chemotherapy.
    PLoS One. 2019;14:e0210991.
    PubMed     Text format     Abstract available
    
    
53. STEINER M, Schneider L, Yillah J, Gerlach K, et al
    FUSE binding protein 1 (FUBP1) expression is upregulated by T-cell acute lymphocytic leukemia protein 1 (TAL1) and required for efficient erythroid differentiation.
    PLoS One. 2019;14:e0210515.
    PubMed     Text format     Abstract available
    
    
54. SCHEICH S, Koenig R, Wilke AC, Lindner S, et al
    Stenotrophomonas maltophilia colonization during allogeneic hematopoietic stem cell transplantation is associated with impaired survival.
    PLoS One. 2018;13:e0201169.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: